Etamycin as a Novel Inhibitor.

Int J Mol Sci

Molecular Mechanisms of Antibiotics, Division of Life Science, Research Institute of Life Science, Division of Applied Life Science (BK21plus Program), Gyeongsang National University, Jinju 52828, Korea.

Published: September 2020

The increase in drug-resistant , which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against . We found that etamycin significantly inhibited the growth of wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish () infection model was greater than that of clarithromycin, which is recommended as the core agent for treating infections. Thus, we concluded that etamycin is a potential anti- candidate for further development as a clinical drug candidate.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555287PMC
http://dx.doi.org/10.3390/ijms21186908DOI Listing

Publication Analysis

Top Keywords

inhibited growth
8
etamycin
5
etamycin novel
4
novel inhibitor
4
inhibitor increase
4
increase drug-resistant
4
drug-resistant resistant
4
resistant existing
4
existing standard-of-care
4
standard-of-care agents
4

Similar Publications

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within preexisting benign lesions called plexiform neurofibromas (PNs). PNs are solely driven by biallelic loss eliciting RAS pathway activation, and they respond favorably to MEK inhibitor therapy.

View Article and Find Full Text PDF

is a dominant member of the human gut microbiome and produces short-chain fatty acids (SCFAs). These promote immune system function and inhibit inflammation, making this microbe important for human health. Lactate is a primary source of gut SCFAs but its utilization by has not been explored.

View Article and Find Full Text PDF

Purpose: Breast cancer ranks as the most prevalent cancer in women, characterized by heightened fatty acid synthesis and glycolytic activity. Fatty acid synthase (FASN) is prominently expressed in breast cancer cells, regulating fatty acid synthesis, thereby enhancing tumor growth and migration, and leading to radioresistance. This study aims to investigate how FASN inhibition affects cell proliferation, migration, and radioresistance in breast cancer, as well as the mechanisms involved.

View Article and Find Full Text PDF

Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction.

J Med Chem

January 2025

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.

MTDH-SND1 protein-protein interaction (PPI) plays an important role in the initiation and development of tumors, and it is a target for the treatment of breast cancer. In this study, we identified and synthesized a series of novel small-molecule inhibitors of MTDH-SND1 PPI. The representative compound showed potent activity against MTDH-SND1 PPI with an IC of 487 ± 99 nM and tight binding to the SND1-purified protein with a value of 279 ± 17 nM.

View Article and Find Full Text PDF

Background: Bushen-Huoxue-Mingmu-Formula (MMF) has achieved definite clinical efficacy. However, its mechanism is still unclear.

Objective: Investigating the molecular mechanism of MMF to protect retinal ganglion cells (RGCs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!